Literature DB >> 19938885

Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.

João Soares1.   

Abstract

We present the case of a patient taking aspirin and etoricoxib who was admitted with upper digestive haemorrhage due to duodenal ulcer. With this case we emphasize that the potential of the stomach-protecting properties of COX-2 selective inhibitors may be reduced in patients who are simultaneously taking aspirin. We also review several pathogenic mechanisms that have been advanced by animal studies to explain the finding that a COX-2 selective inhibitor plus low-dose aspirin leads to an ulcer rate near that of a dual COX-1/COX-2 inhibitor alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19938885     DOI: 10.2165/1153100-S0-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  11 in total

Review 1.  Aspirin.

Authors:  E H Awtry; J Loscalzo
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

2.  Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage.

Authors:  Stefano Fiorucci; Octavio Menezes de Lima; Andrea Mencarelli; Barbara Palazzetti; Eleonora Distrutti; Webb McKnight; Michael Dicay; Li Ma; Mario Romano; Antonio Morelli; John L Wallace
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

3.  Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.

Authors:  H T Sørensen; L Mellemkjaer; W J Blot; G L Nielsen; F H Steffensen; J K McLaughlin; J H Olsen
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

4.  Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis.

Authors:  S Derry; Y K Loke
Journal:  BMJ       Date:  2000-11-11

5.  Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.

Authors:  L M Lichtenberger; J J Romero; E J Dial
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

6.  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Authors:  Loren Laine; Sean P Curtis; Byron Cryer; Amarjot Kaur; Christopher P Cannon
Journal:  Lancet       Date:  2007-02-10       Impact factor: 79.321

7.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors:  Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Patrice Matchaba; Alberto Gimona; Christopher J Hawkey
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Authors:  Loren Laine; Eric S Maller; Chang Yu; Hui Quan; Thomas Simon
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

Review 9.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.

Authors:  C J Hawkey; M J S Langman
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

10.  Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach.

Authors:  H Ukawa; H Yamakuni; S Kato; K Takeuchi
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.